Journal
JOURNAL OF INFECTIOUS DISEASES
Volume 204, Issue 11, Pages 1811-1815Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/infdis/jir636
Keywords
-
Categories
Funding
- Italian Ministry of University and Research
Ask authors/readers for more resources
Novel integrase inhibitors are in advanced clinical development, and cross-resistance data are needed to consider the possibility to plan a sequential usage within this class of antiretroviral drugs. Ex vivo phenotypic assays were conducted on 11 wild-type and 27 fully replicating recombinant viruses obtained from 11 patients failing previous raltegravir-containing regimens. Dolutegravir maintained its activity in vitro on viruses with mutations in position 143 and 155. However, viruses with mutation Q148R associated with secondary mutations and the combination Q148H + G140S were instead associated with a reduced level of susceptibility to dolutegravir in vitro.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available